Related Experiment Video
Updated: Oct 2, 2025

Upper-extremity Approach for Secondary Access in Transfemoral Transcatheter Aortic Valve Implantation
Published on: August 8, 2025
Outcomes, Trends, and Predictors of Gastrointestinal Bleeding in Patients Undergoing Transcatheter Aortic Valve
Salman Zahid1, Muhammad Zia Khan2, Jay Bapaye1
1Department of Medicine, Rochester General Hospital, Rochester, New York.
Insights
Gastrointestinal bleeding (GIB) is a serious complication following transcatheter aortic valve implantation (TAVI). Arteriovenous malformation, peptic ulcer disease, and colorectal cancer significantly increase GIB risk, leading to higher mortality and healthcare costs.
Area of Science:
- Cardiology and Gastroenterology
- Interventional Cardiology
- Gastrointestinal Bleeding Research
Background:
- Transcatheter aortic valve implantation (TAVI) is a common procedure for aortic stenosis.
- Major bleeding, including gastrointestinal bleeding (GIB), is a significant complication post-TAVI.
- Understanding GIB incidence and predictors is crucial for patient management.
Purpose of the Study:
- To determine the incidence of gastrointestinal bleeding (GIB) after transcatheter aortic valve implantation (TAVI) in the United States.
- To identify predictors and associated comorbidities of GIB in TAVI patients.
- To evaluate the impact of GIB on mortality, hospital costs, and length of stay.
Main Methods:
- Retrospective analysis of the National Inpatient Sample database (2011-2018).
- Inclusion of 216,023 hospitalizations for TAVI.
- Propensity-score matching to compare patients with and without GIB.
Main Results:
- The incidence of GIB after TAVI was 1% (2,188 patients).
- Arteriovenous malformation (OR 24.8), peptic ulcer disease (OR 8.74), and colorectal cancer (OR 7.89) were strong predictors of GIB.
- Comorbidities like chronic kidney disease, congestive heart failure, liver disease, end-stage renal disease, atrial fibrillation, and lung cancer were also associated with increased GIB risk. Patients with GIB experienced higher mortality (12.1% vs 3.2%), increased median cost ($68,779 vs $46,995), and longer hospital stays (11 vs 3 days).
Conclusions:
- Gastrointestinal bleeding is associated with significantly higher mortality, healthcare costs, and length of hospital stay following TAVI.
- Pre-existing conditions such as peptic ulcer disease, chronic kidney disease, liver disease, atrial fibrillation, and colorectal cancer are key predictors of GIB post-TAVI.
- Identifying and managing these risk factors is essential for improving outcomes in TAVI patients.
Abstract:
Major bleeding has been identified as one of the most common complications after transcatheter aortic valve implantation (TAVI) with some suffering gastrointestinal bleeding (GIB). This study aimed at assessing the incidence and predictors of GIB after TAVI in the United States. We performed a retrospective analysis of data from the National Inpatient Sample database from 2011 to 2018. A total of 216,023 hospitalizations for TAVI were included. Of the included patients, 2,188 (1%) patients had GIB, whereas 213,835 (99%) patients did not have GIB. The presence of arteriovenous malformation was associated with the highest odds of having a gastrointestinal bleed (odds ratio (OR) 24.8, 95% confidence interval (CI) 17.13 to 35.92). Peptic ulcer disease was associated with an eightfold increased risk of bleeding (OR 8.74, 95% CI, 6.69 to 11.43) followed closely by colorectal cancer (OR 7.89, 95% CI, 5.33 to 11.70). Other comorbidities that were associated with higher propensity-matched rates of GIB were chronic kidney disease (OR 1.27,95% CI, 1.14 to 1.41), congestive heart failure (OR 1.18, 95% CI,1.06 to 1.32), liver disease (OR1.83, 95% CI,1.53 to 2.19), end-stage renal disease (OR 2.08,95% CI, 1.75 to 2.47), atrial fibrillation (OR1.63,95% CI, 1.49 to 1.78), and lung cancer (OR 2.80, 95% CI,1.77 to 4.41). Patients with GIB had higher propensity-matched rates of mortality than those without GIB, (12.1% vs 3.2%, p <0.01). Patients with GIB had a higher median cost of stay ($68,779 vs $46,995, p <0.01) and a longer length of hospital stay (11 vs 3 days, p <0.01). In conclusion, health care use and mortality are higher in hospitalizations of TAVI with a GIB. Baseline comorbidities like peptic ulcer disease, chronic kidney disease, liver disease, atrial fibrillation and, colorectal cancer are significant predictors of this adverse event.
More Related Videos
Related Concept Videos
Aneurysm III: Interprofessional Care
Aneurysm IV: Nursing Management
Esophageal Varices-II: Clinical Features and Management
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
Venous Thrombosis IV: Nursing Management
Aortic Regurgitation I: Introduction
Venous Thrombosis III: Interprofessional Care

